Cancer Family
Soft Tissue Neoplasm
CI-CAN-00000354Explore in graph →
Non-malignant441 active trials9 approved drugs183 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000354Explore in graph →
Clinical trials
2,078 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT03660930 |
| Nab-Sirolimus and Pazopanib Hydrochloride in Treating Patients With Advanced Nonadipocytic Soft Tissue Sarcomas |
| terminated |
| Phase 1 / Phase 2 |
| 19 |
| University of WashingtonOTHER |
| 1 |
| Apr 30, 2025 |
| clinicaltrials |
| NCT06705075 | Evaluation of Uterine Fibroids by CEUS and SHAPE Pre and Post UAE | recruiting | Phase 2 | 80 | Thomas Jefferson UniversityOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05497843 | Chiauranib for Advanced or Unresectable Soft Tissue Sarcoma(STS) | completed | Phase 2 | 40 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Apr 3, 2025 | clinicaltrials |
| NCT04506008 | Hypofractionated Radiotherapy Followed by Surgical Resection in the Treatment of Soft Tissue Sarcomas | recruiting | Phase 2 | 40 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05146440 | Multicohort Trial of Different Schemes of PM14 in Monotherapy and in Combination with Radiotherapy in Soft Tissue Sarcomas and Other Solid Tumor(PRIME) | recruiting | Phase 1 / Phase 2 | 195 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05809830 | Phase I/II of LB-100 Plus Doxorubicin vs. Doxorubicin Alone in First Line of Advanced Soft Tissue Sarcomas(Enhancer) | active not recruiting | Phase 1 / Phase 2 | 152 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT00942877 | Phase II Study of Cediranib (AZD2171) in Patients With Alveolar Soft Part Sarcoma | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Mar 3, 2025 | clinicaltrials |
| NCT04282980 | A Study of DCC-2618 (Ripretinib) In Patients With With Advanced Gastrointestinal Stromal Tumors (GIST) | completed | Phase 2 | 39 | Zai Lab (Shanghai) Co., Ltd.INDUSTRY | 1 | Mar 3, 2025 | clinicaltrials |
| NCT06836505 | Safety and Efficacy of CAR-T Cell Therapy for Relapsed/refractory Neuroblastoma and Desmoplastic Small Round Cell Tumors: a Single-arm, Open-label Trial. | recruiting | Phase 1 / Phase 2 | 10 | Sun Yat-Sen University Cancer CenterOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT02428192 | Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2025 | clinicaltrials |
| NCT03138161 | SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue Sarcoma | recruiting | Phase 1 / Phase 2 | 250 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT04165330 | Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 56 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 24, 2025 | clinicaltrials |
| NCT06494787 | A Phase 2 Study Using Aliya PEF Plus Pembro for Sarcoma(SOC-2320) | withdrawn | Phase 2 | 0 | Sarcoma Oncology Research Center, LLCOTHER | 0 | Feb 24, 2025 | clinicaltrials |
| NCT04095221 | A Study of the Drugs Prexasertib, Irinotecan, and Temozolomide in People With Desmoplastic Small Round Cell Tumor and Rhabdomyosarcoma | completed | Phase 1 / Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 20, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT02401815 | CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 51 | Cogent Biosciences, Inc.INDUSTRY | 1 | Feb 14, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 | clinicaltrials |
| NCT04733183 | Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma(FLASH) | active not recruiting | Phase 2 | 98 | Philogen S.p.A.INDUSTRY | 5 | Jan 27, 2025 | clinicaltrials |
| NCT00780494 | Ph II of Capecitabine, Carboplatin & Bevacizumab for Gastroesophageal Junction & Gastric Carcinoma | completed | Phase 2 | 35 | Stanford UniversityOTHER | 1 | Jan 14, 2025 | clinicaltrials |
| NCT06456359 | Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor(PAMSARC) | recruiting | Phase 2 | 28 | University Hospital HeidelbergOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT05688280 | Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS(INJECTABL-1) | active not recruiting | Phase 1 / Phase 2 | 42 | Immunophotonics, Inc.INDUSTRY | 5 | Jan 8, 2025 | clinicaltrials |
| NCT04791228 | A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors | withdrawn | Phase 2 | 0 | Children's National Research InstituteOTHER | 1 | Jan 1, 2025 | clinicaltrials |
| NCT03241745 | A Study of Nivolumab in Selected Uterine Cancer Patients | completed | Phase 2 | 35 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT06115408 | Evaluation of Using Dienogest and N-Acetyl Cysteine on the Volume of Uterine Leiomyoma | completed | Phase 2 / Phase 3 | 40 | Ain Shams UniversityOTHER | 1 | Dec 16, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT05017103 | Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study | terminated | Phase 2 | 6 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 11, 2024 | clinicaltrials |
| NCT03838744 | Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.(TOMAS2) | completed | Phase 2 | 130 | Italian Sarcoma GroupNETWORK | 1 | Dec 4, 2024 | clinicaltrials |
| NCT05824975 | A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | recruiting | Phase 1 / Phase 2 | 358 | GI Innovation, Inc.INDUSTRY | 2 | Nov 25, 2024 | clinicaltrials |
| NCT03250325 | Study of TBI-1301 (NY-ESO-1 T Cell Receptor Gene Transduced Autologous T Lymphocytes) in Patients with Synovial Sarcoma | completed | Phase 1 / Phase 2 | 8 | Takara Bio Inc.INDUSTRY | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06694324 | First-line Treatment of Advanced/unresectable DDLPS | not yet recruiting | Phase 2 | 49 | Fudan UniversityOTHER | 1 | Nov 19, 2024 | clinicaltrials |
| NCT06217536 | Neoadjuvant Lurbinectedin and Preoperative Radiation for Treating Soft Tissue Sarcomas | withdrawn | Phase 1 / Phase 2 | 0 | University of California, San FranciscoOTHER | 0 | Nov 18, 2024 | clinicaltrials |
| NCT03116529 | Neoadjuvant Durvalumab and Tremelimumab Plus Radiation for High Risk Soft-Tissue Sarcoma(NEXIS) | terminated | Phase 1 / Phase 2 | 22 | University of Maryland, BaltimoreOTHER | 1 | Nov 4, 2024 | clinicaltrials |
| NCT04887298 | Study of Liposomal Annamycin for the Treatment of Subjects with Soft-Tissue Sarcomas (STS) with Pulmonary Metastases | completed | Phase 1 / Phase 2 | 36 | Moleculin Biotech, Inc.INDUSTRY | 1 | Oct 24, 2024 | clinicaltrials |
| NCT03345485 | Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.(EDO-S101) | completed | Phase 1 / Phase 2 | 71 | Mundipharma Research LimitedINDUSTRY | 5 | Oct 21, 2024 | clinicaltrials |
| NCT06637007 | Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma | recruiting | Phase 2 | 30 | Shanxi Province Cancer HospitalOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT04166006 | A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.(RaC-Ad) | recruiting | Phase 2 | 51 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06593899 | The Total Neoadjuvant Therapy for Soft Tissue Sarcoma of the Extremities | unknown | Phase 2 | 51 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT01863745 | Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment | completed | Phase 2 | 15 | Novartis PharmaceuticalsINDUSTRY | 1 | Aug 19, 2024 | clinicaltrials |
| NCT03277924 | Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas(ImmunoSarc) | completed | Phase 1 / Phase 2 | 197 | Grupo Espanol de Investigacion en SarcomasOTHER | 3 | Aug 13, 2024 | clinicaltrials |
| NCT06551896 | Pemigatinib and Immune Checkpoint Inhibitor Treated FGFR1/2/3 Alteration Advanced Solid Tumor | not yet recruiting | Phase 2 | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 0 | Aug 13, 2024 | clinicaltrials |
| NCT01294202 | A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST | completed | Phase 2 | 26 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT03338959 | Pembrolizumab and Radiation Therapy in Treating Patients With Intermediate or High-Grade Soft Tissue Sarcoma | completed | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT06514313 | Clinical Trial of VIM With VIT in Children With Relapsed and Refractory Soft Tissue Sarcoma. | recruiting | Phase 2 | 110 | Yizhuo ZhangOTHER | 1 | Jul 23, 2024 | clinicaltrials |
| NCT00290251 | Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914 | completed | Phase 2 | 72 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH | 1 | Jul 15, 2024 | clinicaltrials |
| NCT06500091 | TQB2916 Injection Combined With Chemotherapy or Penpulimab Injection in the Treatment of Solid Tumors | not yet recruiting | Phase 2 | 54 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd.INDUSTRY | 1 | Jul 15, 2024 | clinicaltrials |
| NCT02636725 | Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | completed | Phase 2 | 33 | Jonathan Trent, MD, PhDOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT05349643 | A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT | completed | Phase 2 | 20 | AmMax Bio, Inc.INDUSTRY | 3 | Jul 5, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 8, 2025source: clinicaltrials